Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn's Disease: A Retrospective Claims Database Analysis.
Ryan C UngaroJenny GriffithViviana Garcia-HortonAolin WangRaymond K CrossPublished in: Crohn's & colitis 360 (2022)
Patients with CD treated with adalimumab as their first biologic experienced significantly lower CD-related HRU and were more likely to discontinue corticosteroids compared to vedolizumab-treated patients.
Keyphrases
- rheumatoid arthritis
- ulcerative colitis
- healthcare
- newly diagnosed
- end stage renal disease
- ejection fraction
- chronic kidney disease
- juvenile idiopathic arthritis
- prognostic factors
- patients with inflammatory bowel disease
- peritoneal dialysis
- disease activity
- hiv infected
- health insurance
- emergency department
- systemic lupus erythematosus
- hidradenitis suppurativa
- antiretroviral therapy
- drug induced